Benefical effects of reteplase in combination with abciximab: Platelet/leukocyte interactions and coagulation system

International Journal of Clinical Pharmacology Research

Volumn 23, Issue 2-3, 2003, Pages 37-40

  Szabo, S ^a,c   Walter, T ^b   Etzel, D ^b   Ehlers, R ^b   Kazmaier, S ^b   Beyer, M E ^b   Hoffmeister, H M ^a  

^a Pathologisches Institut   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c STÄDTISCHES KLINIKUM SOLINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; RETEPLASE; THROMBIN ANTITHROMBIN COMPLEX;

ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOTTING; CELL INTERACTION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM; FIBRINOLYSIS; GRANULOCYTE; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HEMOSTASIS; HUMAN; INFLAMMATION; LEUKOCYTE; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; ST SEGMENT ELEVATION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TISSUE INJURY;

ANTIBODIES, MONOCLONAL; ANTITHROMBIN III; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; GRANULOCYTES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MYOCARDIAL INFARCTION; PEPTIDE HYDROLASES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 1442314009     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Hoffmeister H.M., Szabo S., Kastner C., et al. Thrombolytic therapy in acute myocardial infarction: Comparison of procoagulant effects of streptokinase and alteplase regimen with locus on the kallikrein system and plasmin. Circulation, 98, 2527, 1998.
2. Fitzgerald D.J., Catella F., Roy L., FitzGerald G.A. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation, 77, 142, 1988.
3. Kerins D.M., Roy L., Fitzgerald D.J. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation, 80, 1718, 1989.
4. Szabo S., Letsch R., Ehlers R., et al. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction. Comparison of single bolus tenecteplase and front-loaded alteplase. Thromb. Res., 106, 113, 2002.
5. Ewald G.A., Eisenberg P.R. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation, 91, 28, 1995.
6. Topol E.J., Califf R.M., Van de Werf F., Willerson J.T. and the GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy of combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet, 357, 1905, 2001.
7. Winn R., Vedder N., Ramamoorthy C., Sharar S., Harlan J. Endothelial and leukocyte adhesion molecules in inflammation and disease. Blood Coagul. Fibrinolysis, 9 (Suppl), S17, 1998.
8. Meisel S.R., Shapiro H., Radnay J., et al. Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand IGAM-1 and VLA-4 throughout the acute phase of myocardial infarction: Possible implications for leukocyte aggregation and microvascular plugging. J. Am. Coll. Cardiol., 31, 120, 1998.
9. Furie B., Furie B.C. Leukocyte crosstalk at the vascular wall. Thromb. Haemost., 78, 306, 1997.